A Malvern-based biotechnology company known for its gene therapies and vaccines, is expecting to raise $16.5 million through a public stock offering, writes…

Malvern-based Ocugen has entered into an exclusive license agreement with Washington University for the rights to develop, manufacture, and commercialize its intranasally delivered COVID…

Malvern-based Ocugen announced positive feedback for pediatric clinical testing of its version of the COVID-19 vaccine as the biopharmaceutical company attempts to bring…

At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…

Malvern-based Ocugen, which is working to bring the Covaxin COVID-19 vaccine to the U.S., has entered into a deal to buy a…

Public companies in the Philadelphia area added nearly $122 million to their market caps in 2021. Six of those that saw their value increase the…

Malvern-based Ocugen has submitted a request to the Food and Drug Administration for Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate for…

Malvern-based Ocugen submitted an investigational new drug application with the FDA. It seeks approval to start a Phase-3 clinical trial that would evaluate…

Malvern-based Ocugen has encountered a significant obstacle in its plans to bring the COVID-19 vaccine developed in India to the U.S., writes…

Malvern-based Ocugen collaborated with India’s Bharat Biotech to develop a fourth vaccine, and it could be a game-changer in the ongoing fight…

Later this month, Malvern-based Ocugen will seek an emergency-use authorization from the FDA to cooperate with Bharat Biotech for the India-based company…

Malvern-based Ocugen’s stock increased nearly 201 percent after announcing its plans for a direct stock offering worth $23 million, writes John George for…

Malvern-based Ocugen has finalized a deal with Bharat Biotech to develop the India-based company’s COVID-19 vaccine, Covaxin, for the U.S…

The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based…

Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the…

Ocugen, a gene therapy and biopharmaceutical company in Malvern, has finalized its reverse merger with Histogenics, a publicly traded company in Boston, and is now…

Malvern-based Ocugen, a gene therapy and biopharmaceutical company that develops new treatments for rare and underserved eye diseases, has entered into a merger agreement…